Hormonal
Fructose uniquely upregulates the transcription factor SREBP1c and downstream fatty acid synthesis genes, leading to reduced liver insulin signaling, whereas glucose upregulates ChREBP and triglyceride synthesis without impairing insulin signaling.
Understanding how different sugars affect your liver can help you make better choices. Fructose drives fat production and insulin resistance through specific genetic pathways (SREBP1c), while glucose may actually support insulin sensitivity. If you consume high-fat meals, minimizing fructose (soda, candy) is more critical for metabolic health than avoiding glucose sources.
While both sugars increased ChREBP-β, fructose supplementation uniquely increased SREBP1c and downstream fatty acid synthesis genes, resulting in reduced liver insulin signaling. In contrast, glucose enhanced total ChREBP expression and triglyceride synthesis but was associated with improved hepatic insulin signaling.
Why this rating
Robust mechanistic data using RNA-seq, Western blots, and metabolomics in a controlled animal model.
Source
Divergent effects of glucose and fructose on hepatic lipogenesis and insulin signaling
Samir Softic et al. · Journal of Clinical Investigation · 2017
DOI 10.1172/jci94585
More from this paper
- In the presence of a high-fat diet, fructose supplementation causes pronounced obesity, glucose intolerance, and hepatic insulin resistance, whereas glucose supplementation does not cause these metabolic deficits despite similar caloric intake.Good
- Knocking down Ketohexokinase (KHK), the first enzyme in fructose metabolism, improves hepatic steatosis and glucose tolerance in fructose-supplemented mice.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →